Compare AXGN & GSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AXGN | GSBD |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | 452 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | AXGN | GSBD |
|---|---|---|
| Price | $30.58 | $9.33 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 9 | 1 |
| Target Price | ★ $33.67 | $9.00 |
| AVG Volume (30 Days) | 922.8K | ★ 1.5M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 13.79% |
| EPS Growth | N/A | ★ 69.72 |
| EPS | N/A | ★ 1.14 |
| Revenue | $214,709,000.00 | ★ $383,307,000.00 |
| Revenue This Year | $21.60 | N/A |
| Revenue Next Year | $15.83 | N/A |
| P/E Ratio | ★ N/A | $8.13 |
| Revenue Growth | ★ 18.72 | N/A |
| 52 Week Low | $9.22 | $9.26 |
| 52 Week High | $34.24 | $13.45 |
| Indicator | AXGN | GSBD |
|---|---|---|
| Relative Strength Index (RSI) | 51.59 | 36.00 |
| Support Level | $32.03 | $9.51 |
| Resistance Level | $33.84 | $9.70 |
| Average True Range (ATR) | 1.39 | 0.14 |
| MACD | -0.32 | -0.05 |
| Stochastic Oscillator | 32.41 | 22.16 |
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests primarily in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.